XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.22.1

Liabilities Related to Sales of Future Royalties | 3 Months Ended
--- | ---
Mar. 31, 2022
Other Liabilities Disclosure [Abstract] |
Liabilities Related to Sales of Future Royalties | Liabilities Related to Sales of Future Royalties In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:
Drug | Manufacturer | Counterparty under Purchase and Sale Agreement | Date Sold
ADYNOVATE® and ADYNOVI® (brand name for ADYNOVATE® in Europe) | Takeda Pharmaceutical Company Limited | Healthcare Royalty Management, LLC | December 16, 2020
MOVANTIK® (naloxegol tablets) and MOVENTIG® (brand name for MOVANTIK® in Europe) | AstraZeneca AB | Healthcare Royalty Management, LLC | December 16, 2020
REBINYN® | Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G | Healthcare Royalty Management, LLC | December 16, 2020
CIMZIA® (certolizumab pegol) | UCB Pharma | RPI Finance Trust | February 24, 2012
MIRCERA® (Continuous Erythropoietin Receptor Activator) | F. Hoffmann-La Roche Ltd | RPI Finance Trust | February 24, 2012
Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. The following table shows the activity within the liability account of each arrangement (in thousands):
| Period from inception to March 31, 2022
| 2012 Purchase and Sale Agreement |  | 2020 Purchase and Sale Agreement |  | Total
Royalty monetization proceeds | $ | 124,000 |  |  | $ | 150,000 |  |  | $ | 274,000 |
Non-cash royalty revenue | (289,655) |  |  | (61,357) |  |  | (351,012) |
Non-cash interest expense | 226,506 |  |  | 25,296 |  |  | 251,802 |
Payments to RPI | (10,000) |  |  | — |  |  | (10,000) |
Loss on revaluation of liability related to the sale of future royalties (1) | 23,522 |  |  | — |  |  | 23,522 |
Liabilities related to the sales of future royalties – ending balance | 74,373 |  |  | 113,939 |  |  | 188,312 |
Less: unamortized transaction costs | — |  |  | (2,708) |  |  | (2,708) |
Liabilities related to the sales of future royalties, net | $ | 74,373 |  |  | $ | 111,231 |  |  | $ | 185,604 |
(1) Loss recognized from Settlement Agreement to resolve UCB’s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.
We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of March 31, 2022, our imputed interest rates for the arrangements with RPI and HCR were 16% and 15%, respectively.

X
- Definition Liability related to sale of potential future royalties. + References No definition available. + Details
Name: | nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
Namespace Prefix: | nktr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration